Literature DB >> 11773147

Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"?

Mark J Ratain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11773147     DOI： 10.1200/JCO.2002.20.1.7

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

Review 1.  Review of systemic therapies for locally advanced and metastatic rectal cancer.

Authors:  Patrick Yaffee; Arsen Osipov; Carlyn Tan; Richard Tuli; Andrew Hendifar
Journal:  J Gastrointest Oncol       Date:  2015-04

2.  MiR-218 and miR-100 polymorphisms as markers of irinotecan-based chemotherapy response in metastatic colorectal cancer.

Authors:  Dimitra-Ioanna Lampropoulou; Gerasimos Aravantinos; Konstantinos Laschos; Theodosis Theodosopoulos; Christos Papadimitriou; Maria Gazouli
Journal:  Int J Colorectal Dis       Date:  2019-10-09       Impact factor: 2.571

3.  All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide.

Authors:  Spinel Karas; Federico Innocenti
Journal:  JCO Oncol Pract       Date:  2021-12-03

4.  Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites.

Authors:  Zheng Liu; Jennifer H Martin; Winston Liauw; Sue-Anne McLachlan; Emma Link; Anetta Matera; Michael Thompson; Michael Jefford; Rod J Hicks; Carleen Cullinane; Athena Hatzimihalis; Ian Campbell; Simone Crowley; Phillip J Beale; Christos S Karapetis; Timothy Price; Mathew E Burge; Michael Michael
Journal:  Eur J Clin Pharmacol       Date:  2021-09-04       Impact factor: 2.953

Review 5.  Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.

Authors:  J M Campbell; M D Stephenson; E Bateman; M D J Peters; D M Keefe; J M Bowen
Journal:  Pharmacogenomics J       Date:  2016-08-09       Impact factor: 3.550

6.  Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients.

Authors:  Spinel Karas; Amy S Etheridge; Eleftheria Tsakalozou; Jacqueline Ramírez; Erika Cecchin; Ron H N van Schaik; Giuseppe Toffoli; Mark J Ratain; Ron H J Mathijssen; Alan Forrest; Robert R Bies; Federico Innocenti
Journal:  AAPS J       Date:  2020-03-17       Impact factor: 4.009

7.  Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.

Authors:  Crystal S Denlinger; Rebecca Blanchard; Lu Xu; Coen Bernaards; Samuel Litwin; Cynthia Spittle; Daniel J Berg; Susan McLaughlin; Maryann Redlinger; Andrew Dorr; Julie Hambleton; Scott Holden; Anne Kearns; Sara Kenkare-Mitra; Bert Lum; Neal J Meropol; Peter J O'Dwyer
Journal:  Cancer Chemother Pharmacol       Date:  2009-05-05       Impact factor: 3.333

8.  Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats.

Authors:  Marina Fittkau; Wieland Voigt; Hans-Jürgen Holzhausen; Hans-Joachim Schmoll
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

9.  A population-based clinical trial of irinotecan and Carboplatin.

Authors:  Derick Lau; Minh Huynh; Jewel Johl
Journal:  J Oncol       Date:  2009-04-23       Impact factor: 4.375

10.  Polymorphisms of UGT1A1*6, UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia.

Authors:  L K Teh; H Hashim; Z A Zakaria; M Z Salleh
Journal:  Indian J Med Res       Date:  2012-08       Impact factor: 2.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.